Desmoid Tumors CTOS 2024 Preview
An Expert’s Guide to CTOS 2024: Preview of the Top Desmoid Tumor Abstracts

Released: November 14, 2024

Expiration: November 13, 2025

Ravin Ratan
Ravin Ratan, MD

Activity

Progress
1
Course Completed

The 2024 Connective Tissue Oncology Society (CTOS) will feature significant results from numerous clinical studies in connective tissue cancers, including desmoid tumors. As part of CCO’s Independent Conference Coverage of CTOS 2024, Ravin Ratan, MD identified his most anticipated abstracts in desmoid tumors, listed below. Remember to check the CCO website often as the meeting unfolds for downloadable slidesets summarizing the data from these studies.

  • Long-term results from DEFI: Long-term efficacy and safety data from the phase III trial of the gamma secretase inhibitor, nirogacestat, compared with placebo in adult patients with desmoid tumors (abstract 103). Longer-term data are especially important in demonstrating consistent efficacy benefit over time.
  • DEFI Subgroup Analysis: A post hoc analysis of the phase III trial of nirogacestat vs placebo in patients with desmoid tumors and poor prognostic factors (abstract 102). Patient-reported outcomes, progression-free survival, and objective response rate are reported.
  • An observational prospective study on longitudinal immunological profiling in patients with desmoid fibromatosis under active surveillance (abstract 104). Analysis of this study may reveal how the immune system shapes the clinical disease course and overall patient outcomes.
  • Early real-world experience with nirogacestat in patients with desmoid fibromatosis is also explored (abstract 35). It is critical for healthcare professionals to be aware of how patients respond to nirogacestat in real-world settings beyond what we have experienced in the select groups of patients in clinical trials.
  • A real-world retrospective review of multidisciplinary management of intra-abdominal desmoid-type fibromatosis is also discussed (abstract 380). Learnings from a 30-year period will be covered.

Poll

1.

Which of types of presentations are you most interested in hearing more about at CTOS 2024?

Submit